APOS health equity scholar Angela Mendez sharing strategies to adapt supportive care interventions for minoritized men with prostate cancer on ADT. ⁦Daniel Lage, MD, MBA⁩ ⁦Mass General Cancer Center⁩ ⁦APOS⁩ #apos2024

One more top 5 #bladdercancer -- which may be most anticipated GU track ESMO - Eur. Oncology #ESMO23 -- EV-302 looks to be game changer/paradigm shifting for our patients with metastatic #bladdercancer . Also double ADCs together and new data w/ FGFR inhibitors! OncoAlert Bladder Cancer Advocacy Network

Proud to highlight prostate cancer health disparities and the need for better screening and outreach alongside amazing colleagues Mass General Cancer Center Rick Lee 이재방 Brenda Lormil Beverly Moy #EdwinChoy Also, the Boston Rhythm Riders Line Dancers have some impressive moves, so fun!!

25% of days from diagnosis to death in metastatic GI cancer are spent in an inpt or outpt facility. Drives home the need for home-based oncology care delivery models as a win for patient experience and costs ascopubs.org/doi/full/10.12… JCO Oncology Practice Arjun Gupta Gabrielle Ryan Nipp, MD, MPH

Thoughtful discussion of the next frontier and challenges in value-based oncology: buff.ly/42X33ML I think the transition from FFS to capitated/global payments will be more challenging than most anticipate, but ultimately beneficial for patients & care deliver innovation

What’s the hardest part of being an oncologist? Giving difficult news to patients? Keeping up with rapid clinical and scientific advances? No, it’s “Having so many rules and regulations” buff.ly/3pnb2oO

Interesting work. We effectively tell patients to figure it out on their own after hospital discharge. I wonder how that will go for seriously ill patients, those with poor health literacy, socioeconomic status, social supports, etc?? Thanks for sharing Ryan Nipp, MD, MPH

So glad you’re keeping the tradition alive! Visit dinners are the best, so important to connect on a human/social level after spending so much time caring for complex/sick patients. Mass General Cancer Center Rick Lee 이재방

“Patients see home not as a place but as a state of health they were previously in.” Thank you Daniel Lage, MD, MBA for your valuable insights and work! HMS Palliative Care MGH Palliative Care & Geriatric Medicine #hapc

Successful 💪🏽session with all-star ⭐️line up of speakers!!
Rare tumors (penile and seminoma) but lots of great data presented showing that we are indeed moving the needle forward!
ASCO #GU23

Alexandros Papachristofilou +Dr Alice Yu + Dr Ben Ayres

Great point! Agreed that anemia and its impact on health care utilization and QOL needs to be studied much more carefully

A big theme of PROPEL and PARPi in general is how to manage anemia and other toxicities. Would love to see analyses and measures focused on the impact of anemia/cytopenias beyond the FACT-P, and also transfusions, workup and health care utilization due to these AE’s #ASCOGU23

Really helpful subgroup data from ARASENS on how patients with high vs low risk/volume disease benefit from triplet therapy. Builds on last year’s impressive initial results. Will help guide selection of therapy for pts with mHSPC. Journal of Clinical Oncology #GU23 ASCO

Strong start #GU23
Neeraj Agarwal, MD, FASCO presents encouraging results: TALA + ENZA improve PFS in 1L trt for pts w/ #mCRPC
OncoAlert

Great to be at #ASCOGU23 in San Francisco! Starting day 1 with Philz Coffee and learning about the latest in prostate cancer…also a reason to get back on Twitter to share what’s going on in the field! Mass General Cancer Center Rick Lee 이재방 Sophia Kamran, MD

Was privileged to learn from and work with both Christopher Sweeney, MBBS and Guru P. Sonpavde, MD during fellowship Dana-Farber Lank Center for Genitourinary Oncology. Very kind and generous mentors in GU oncology…Best wishes for the future and looking forward to staying in touch!

Happy 12th anniversary to the Temel article.

What a landmark article for #PalliativeCare .

#hapc

nejm.org/doi/10.1056/NE…

We got darolutamide approved for a patient with mHSPC last week before FDA approval, and now it's finally gone through! This will be great for patients, and hopefully very well-tolerated and improve QOL and long-term outcomes. Prostate Cancer Foundation Mass General Cancer Center buff.ly/3Sxn4Wq